Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Running, not enrolling · Phase 2

Conditions studied: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

In brief

The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.

Key facts

Study ID
NCT07161037
Run by
Vertex Pharmaceuticals Incorporated
People needed
26
Starts
2025-11-19
Expected to finish
2027-12-31
Last updated by the study team
2026-07-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.